Prolyl-tRNA synthetase inhibitor as a novel first-in-class keloid treatment: downregulation of <i>de novo</i> collagen synthesis and inflammatory cascade
DWN12088, a selective PRS inhibitor, may be a novel first-in-class treatment modality that effectively prevents keloid development. Further clinical trials are required to verify the safety and clinical efficacy of PRS inhibitors for keloids. We believe that our study has applicability across several fibrotic wound problems such as hypertrophic scars.
Authors
- Joon Seok Park (ORCID: https://orcid.org/0009-0007-1090-6921)
- Ji‐Ung Park (ORCID: https://orcid.org/0000-0002-6403-4918)
- Ki‐Myo Kim
- Sally Min (ORCID: https://orcid.org/0000-0002-7750-6590)
- Caroline H. Lee (ORCID: https://orcid.org/0000-0002-0750-9868)
- Jaewoo Kim (ORCID: https://orcid.org/0000-0002-0967-0882)
- Jun Ho Park (ORCID: https://orcid.org/0000-0003-0235-1261)
- Joseph Hwang
Institutions
- Seoul National University (KR)
- New Generation University College (ET)
- National University College (PR)
- Daewoong Pharmaceutical (South Korea) (KR)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1093/bjd/ljaf140
- Citations
- 1
- Primary Topic
- Dermatologic Treatments and Research
- Type
- article
- Field-Weighted Citation Impact
- 2.00